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Abstract
Elevated plasma homocysteine levels are associated with increased risk for cardiovascular disease and neural tube defects in humans.
Folate treatment decreases homocysteine levels and dramatically reduces the incidence of neural tube defects. The flavoprotein
methylenetetrahydrofolate reductase (MTHFR) is a likely target for these actions of folate. The most common genetic cause of mildly
elevated plasma homocysteine in humans is the MTHFR polymorphism A222V (base change C677→T). The X-ray analysis of E. coli
MTHFR, reported here, provides a model for the catalytic domain that is shared by all MTHFRs. This domain is a β8α8 barrel that
binds FAD in a novel fashion. Ala 177, corresponding to Ala 222 in human MTHFR, is near the bottom of the barrel and distant from
the FAD. The mutation A177V does not affect Km or kcat but instead increases the propensity for bacterial MTHFR to lose its essential
flavin cofactor. Folate derivatives protect wild-type and mutant E. coli enzymes against flavin loss, and protect human MTHFR and the
A222V mutant against thermal inactivation, suggesting a mechanism by which folate treatment reduces homocysteine levels.

composed of subunits of Mr 70,000−77,000. Determinants for
binding of FAD, NAD(P)H and CH2-H4 folate are located in the
N-terminal, Mr 40,000 portion; the C-terminal domain regulates
enzyme activity in response to the demand for adenosylmethionine (AdoMet) and contains the binding site for this allosteric inhibitor. The subunits of MTHFRs of enteric bacteria are
shorter chains ~300 residues in length. Their sequences can be
aligned with the N-terminal catalytic domains of the eukaryotic
MTHFRs13, with 30% identity between the human and E. coli sequences (Figure 1). This level of primary sequence conservation
predicts that the catalytic domains of the human and E. coli enzymes will possess similar structures.14
Many of the clinically significant mutations found so far in
human MTHFR,1, 13, 15, 16 including A222V, affect conserved
residues in the catalytic domain. Human MTHFR has not
yet been expressed at high enough levels to permit purification and biochemical investigation, so to investigate the molecular basis for impaired function in mutant human MTHFRs we have undertaken analyses of the enzyme from E. coli.
The A222V mutation has been mimicked by constructing the
corresponding A177V mutation in E. coli, and we have compared the biochemical properties of the bacterial wild-type
and A177V mutant MTHFR proteins. The X-ray structure of
the wild-type MTHFR from E. coli , reported here, provides a
framework to relate genotypes to molecular phenotypes.

Methylenetetrahydrofolate reductase (MTHFR) catalyzes the
reduction of 5,10-methylenetetrahydrofolate (CH2-H4 folate)
to 5-methyltetrahydrofolate (CH3-H4 folate), as shown in
Equation (1).
CH2-H4 folate + NAD(P)H → CH3-H4 folate + NAD(P)+ (1)
A noncovalently bound flavin adenine dinucleotide (FAD)
cofactor accepts reducing equivalents from NAD(P)H and
transfers them to CH2-H4 folate. Reduction of CH 2-H4 folate
by MTHFR is the only route for synthesis of the CH3-H4 folate
that is utilized by methionine synthase to convert homocysteine to methionine.
Deficiency of MTHFR is the most common inborn error
of folate metabolism and is a major genetic cause of hyperhomocysteinemia. One polymorphism, A222V (base change
677C→T), for which ~10% of the population is homozygous,1,
2, 3, 4 is associated with mildly elevated fasting plasma homocysteine levels, especially in patients with low folate levels5, 6,
7, and with reduced specific activity and increased thermolability of MTHFR in lymphocyte extracts.1, 8 Homozygosity for
the 677C→T mutation is the most common genetic cause of
mildly elevated plasma homocysteine7, 9 and is a risk factor for
the development of cardiovascular disease.1, 2, 3 The T/T genotype in either the mother or the fetus is also a risk factor for
fetal neural tube defects.10 Folic acid treatment decreases homocysteine levels11 and dramatically reduces the incidence of
neural tube defects.12 The molecular bases for the impairment
engendered by the 677C→T mutation and for the beneficial effects of folate are addressed here.
Human and other eukaryotic MTHFRs are dimeric enzymes

The structure of MTHFR
The structure of MTHFR, the first example of a β8α 8 barrel that binds FAD (Figure 2), has been solved using multiwavelength anomalous diffraction (Table 1). The chain tracing
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Figure 1. Alignment of the sequences of E.coli and human
MTHFRs, based on simultaneous alignment of 12 MTHFR
sequences and the positions of secondary structures in
the E.coli enzyme. The locations of helices and β-strands in
the structure are indicated by cylinders and arrows; residues
flagged with asterisks interact with FAD in E. coli MTHFR.
Shaded residues are identical in at least 9 of the 12 aligned
MTHFR sequences. Sites of known mutations in the human
enzyme are designated by black backgrounds, and the corresponding amino acid and nucleotide changes are shown. The
N-terminal methionine is removed from the mature enzyme.

isoalloxazine ring of the FAD to facilitate hydride
transfer. Hydride transfer between the substrates
and the flavin N(5) is known to occur at the si face
of the flavin ring22. Model building suggests that the
p-aminobenzoyl-glutamate moiety of methylenetetrahydrofolate lies in the groove. Thus the unusual truncation of the barrel elements β8 and α8 may be associated with the requirement to bind and react with
the folate substrate.

(Figure 2c) includes 273 residues; 20 N-terminal and two Cterminal residues are not visible in any of the three chains that
compose the asymmetric unit. As expected for enzymes that
form β/α barrels, the cofactor is bound at the C-termini of the
β-strands. The flavin ring lies within the barrel with its plane
parallel to the staves of the barrel and its si face exposed to solvent. The ribityl side chain and phosphate moieties are inserted
between barrel strands 4 and 5, the ribosyl group adjoins helix
5, and the adenosyl group extends over the rim of the barrel.
Other known flavoenzymes that adopt β/α barrel folds bind
flavin mononucleotide (FMN) rather than FAD. These enzymes
— glycolate oxidase,17 flavocytochrome b2 (18), old yellow enzyme,19 trimethylamine dehydrogenase,20 and dihydroorotate
dehydrogenase21 — catalyze a variety of reactions, but FMN
is bound in a similar fashion in all of them. Comparison of
MTHFR with these enzymes shows that MTHFR breaks most
of the structural rules that seemed to be established from the
barrels that bind FMN. In the FMN-binding barrels, the ribityl
phosphate side chain is inserted between strands 7 and 8, and
the FMN phosphates are hydrogen-bonded to amides in the initial turn of a short but conserved helix, α8’, that precedes the
α8-helix of the barrel. In MTHFR the ribityl side chain extends
between barrel strands 4 and 5; there is no equivalent to the
α8’ helix that binds the FMN phosphates, and the flavin ring
is tilted by ~80° from its orientation in the other β8α8 flavoenzymes. The novel aspects of FAD binding in the MTHFR β8α
8 barrel make it difficult to argue for divergent evolution of a
flavin-binding family of barrel enzymes.
From the side view (Figure 2b), it is evident that strand 8
and helix 8 are both truncated relative to the rest of the β/α
elements of the barrel. This truncation opens a groove running from the outer edge of the barrel to the accessible si face
of the flavin. The pyridine nucleotide and folate substrates,
NADH and CH2-H4 folate, are each expected to bind with the
nicotinamide or pterin rings stacked over the open face of the

The FAD-binding site
Electron density corresponding to the flavin ring
and its protein environment has been calculated
(Figure 3a), and the interactions of bound FAD with
some of the conserved residues that form the binding site are depicted in a stereo drawing (Figure
3b). The residues that bind FAD are clustered at the
ends of barrel strands β3, β4, and β5 and along helix α5 (Figs 1, 3b). The composition and spacing of
these MTHFR sequences do not correspond to the
characteristic sequence fingerprints associated with binding of
flavin nucleotides19, 23. The backbone of FAD is crimped by a
kink that buries the pyrophosphate and brings the C5 atoms
of the ribityl and ribose groups into van der Waals contact. In
contrast to many other flavoenzymes, MTHFR does not bind
the flavin phosphate at the initial turn of an α-helix.
An intriguing feature of the FAD-binding site is the belt
of side chains arching over the ribityl and phosphate groups
and secured by the Arg 118−Glu 158 interaction that acts as a
buckle (Figure 3b). The position of these residues suggests a
role for the belt in the thermodynamics and kinetics of FAD
binding. The β5-α5 connector, which includes Glu 158 from
the belt buckle, encloses the ribityl-diphosphate-ribose segments of the FAD, so rearrangements of the protein must
occur to let FAD enter or leave its binding site. One of the
severe mutations in human MTHFR, R157Q (base change
482G→A) (13), alters the belt residue corresponding to Arg
118 in E. coli MTHFR. The role of Arg 118 in the structure
of E. coli MTHFR strongly suggests that the R157Q mutant is
defective in flavin binding.
Characterization of A177V mutant bacterial MTHFR.
The clinically significant A222V polymorphism in human
MTHFR has been mimicked in the E. coli enzyme by introducing the homologous mutation A177V. When the catalytic
properties of the wild-type and A177V mutant enzymes were
compared, the mutation was found not to affect kcat or the K m
values for CH2-H4 folate or NADH. The kinetic parameters of
the wild-type enzyme were determined at 15 °C and pH 7.2 in
a stopped-flow spectrophotometer24: Km for NADH is 17 μM,
Km for CH2-H4 folate is 3.9 μM, and kcat is 1,410 mol NADH
oxidized min−1 (mol enzyme-bound FAD)−1. The A177V mutation does not significantly change the measured kinetic parameters of MTHFR: Km for NADH is 17 μM, Km for CH2-H4
folate is 3.9 μM, and kcat is 1,180 min−1.
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Figure 2. The structure of E. coli MTHFR. a) A
view along the axis of the β8α 8 barrel looking toward the C-terminal ends of the β−strands37. FAD is
drawn in ball-and-stick mode. Helix α5, which precedes the site corresponding to the human A→V
polymorphism, is colored red in this and succeeding
figures. b) A view perpendicular to the barrel axis
and toward the si face of the flavin ring, showing
the truncation of strand β8 and helix α8 and the resulting groove in which methylenetetrahydrofolate
is expected to bind. Ala 177, the site of the Ala→Val
mutation, is drawn with gray dot surfaces, and is
at the rear of the barrel. c) A stereo drawing of the
chain fold from approximately the same perspective
as in ( a).

Studies of the human A222V polymorphism have suggested that the mutant protein is more thermolabile than the
wild-type protein as assessed by measurements of residual
activity after heating lymphocyte extracts for 5 min at 46 °C
(25) and by similar measurements with recombinant mutant
human enzyme expressed in E. coli.1 We investigated whether
the A177V mutation was associated with thermolability of
the bacterial enzyme using differential scanning calorimetry.
The Tm was 53.8 °C for 60 μM mutant enzyme and 60.9 °C for
wild-type protein at the same concentration (Figure 4). Both
wild-type and mutant enzymes denature at progressively
lower temperatures as their concentrations are decreased.
Concentration-dependent melting temperatures are expected
for systems in which an oligomer denatures to form unfolded
protomers26.
Gel filtration was used to demonstrate that E. coli MTHFR
is a tetrameric enzyme that dissociates to dimers rather than
monomers on dilution. When wild-type or A177V enzymes
were applied to a Superose 12 FPLC column at an initial
concentration of 60 μM, the relative molecular masses determined from the elution volumes were 119,000 ±2,000 (3.5
±0.1 subunits mol−1 ) for the wild-type enzyme and 108,000
±10,000 for the mutant. The flavin cofactor remained bound to
the tetrameric enzymes during the gel filtration as indicated
by the flavin absorbance at 450 nm. Dilution of wild-type or
mutant enzymes resulted in dissociation to dimers and loss of
flavin. Dissociation to dimers is consistent with the arrangement of subunits found in the crystal structure. When the
enzymes were applied to the gel column at initial concentrations of 500 nM, the estimated relative molecular masses were
65,000 ±7,000 (1.9 ±0.2 subunits mol−1) for wild-type enzyme
and 59,000 ±4,000 for the mutant enzyme. The flavin was released and eluted later, as indicated by monitoring flavin
fluorescence.

These observations prompted further investigation of FAD binding by the A177V
mutant and wild-type enzymes. FAD bound
to MTHFR is not fluorescent; dissociation
of FAD was therefore followed by measuring the fluorescence associated with the appearance of free flavin. The initial rate of flavin loss from the mutant was ~11 times that
seen with the wild-type enzyme ( Figure 5a,
inset). The final fluorescence after dilution of
the mutant protein to 500 nM indicated that
all the flavin had been released. The enzyme
concentration at which 50% of the flavin dissociated was 1.3 μM for the wild-type enzyme
and 5.9 μM for the mutant protein. These data
imply that the A177V mutation decreases the
affinity of the protein for FAD. In both mutant
and wild-type enzymes the initial rate of FAD
loss varies as the square root of the enzyme
concentration after dilution, as indicated by the fit of the data
to the solid lines (Figure 5a). This dependence would be expected if the dissociation of the tetramer into dimers precedes
the release of flavin. We conclude that the A177V mutation in
the E. coli enzyme shifts the overall equilibrium between holoenzyme tetramers and apoenzyme dimers toward the formation of apoenzyme dimers.
Because FAD is an essential reactant in the enzyme-catalyzed electron transfer from NADH to CH2-H4 folate, flavin
dissociation is accompanied by loss of enzyme activity. Enzyme activity was monitored under the same conditions as
those used for the fluorescence measurements (Figure 5a). The
A177V protein lost activity at a rate 10 times that for the wildtype protein, and the half-time for activity loss was the same
as the half-time for the increase in flavin fluorescence, within
the precision of the measurements (data not shown).
Since folate is known to lower homocysteine levels in the
plasma, and to protect against the development of neural tube
defects, we examined the effects of added folates on the rate
of flavin dissociation and loss of enzyme activity after dilution
of reductase. Addition of CH3-H4 folate (monoglutamate) reduced the rate of flavin loss from both the wild-type and mutant enzymes in a concentration-dependent manner (Figure 5
b). The mutant enzyme requires much higher levels of folate
to decrease the initial rates of flavin loss to the values found
for wild-type. When activity rather than fluorescence was
measured following dilution into a solution containing added
folate derivatives, in an experiment similar to that just mentioned (Figure 5b), the rate of loss of activity was decreased
(data not shown). For E. coli MTHFR equivalent concentrations of CH3-H4 folate triglutamate were more effective than
the monoglutamate at reducing the rate of flavin loss, consistent with the known Km values for polyglutamate substrates.27
Protection was also observed using the inhibitor dihydrofolate
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Figure 3. The FAD-binding site. a) The electron density
in the vicinity of the cofactor, contoured at 1σ. The map
was calculated with amplitudes (2|Fo| - |F c|) and phases
from the final refinement (Table 1); contours within 3 Å
of model atoms are displayed. Residues surrounding
the exposed si face are His 88, Asp 120, Thr 182 and Gln
183; β-strand 2 is in the foreground. b) A stereo drawing showing many of the conserved residues that contact
bound FAD, which is drawn in ball-and-stick mode with
atom coloring. Side-chain carbons are in cyan with oxygen and nitrogen atoms red and blue, respectively. The
belt residues, Arg 118 and Glu 158, are distinguished by
darker stick bonds and dot surfaces.

exists in solution. The tetramer we have designated has larger subunit−subunit contact areas,
and polarities and compositions that are more
characteristic for oligomer interfaces than for
crystal packing contacts.28, 29 The tetramer displays only C2 (two-fold) rather than the customary D2 (222) symmetry. The center of the tetramer
is open, and the chains are held together by just
two kinds of interfaces. The symmetry and packing of the subunits predict that the tetramers will
dissociate to dimers, as observed in gel filtration
of dilute enzyme solutions. The area calculated for
the B−C interface is 800 Å2, while that for the A−B
interface is 500 Å2; this suggests that the tetramer
will dissociate into identical A-A’ and B-C dimers,
across the interface that incorporates helix α5.
Thus if steric overlap of Val 177 with its neighbors
triggers movement of helix α5, the interactions
across this interface will be affected.

monoglutamate and the folate antagonist 5,10-dideazatetrahydrofolate pentaglutamate. We infer that any folate derivative
that binds MTHFR slows the rate of dissociation of the flavin.
Mapping the A177V mutation onto the structure: the molecular phenotype
The A177V mutation affects FAD binding, but alters a residue that is not part of the FAD-binding site. In the E. coli enzyme, Ala 177 is located near the bottom of the β8α8 barrel, out
of direct contact with the flavin or with conserved residues
that may be essential for activity or folate binding (Figs 2b,
6). This residue nestles in the loop connecting helix α5 with
strand β6 and packs against atoms of Lys 172 in the preceding
turn of the α5-helix, and against conserved residues Val 136 in
helix α4 and Val 149 in strand β5. Mutating Ala 177 to valine
is expected to perturb all of these packing interactions and to
affect the secondary structures in which the neighbors of residue 177 reside. Propagation of packing changes to the FADbinding site is easiest to envision as a perturbation of helix α5,
which carries residues Lys 172, Asn 168, and Asp 165 that interact with the phosphate and ribosyl groups of the FAD (Figure 6a).
Interactions between chains of the tetrameric bacterial
MTHFR may also be affected by the A177V mutation. The
packing of chains in the tetramer of E. coli MTHFR is unusual
(Figure 6b). The 12 monomers of the unit cell are arranged in
layers in which either of two approximately planar arrangements of four chains can be selected as the tetramer that

Implications
Our comparison of the phenotypes of wildtype and A177V mutant MTHFR enzymes from
E. coli suggests that the mutation leads to a thermolabile enzyme that loses its flavin cofactor more
readily than does the wild type. This mutation
accentuates properties inherent in the wild-type
enzyme. With both wild-type and mutant enzymes, addition
of folate derivatives results in decreased rates of flavin release
and activity loss. We envision that protection by folate results
from the increased affinity of MTHFR for FAD in the ternary
complexes of enzyme, folate, and FAD.
The structure/function studies of the bacterial enzyme reported here provide a model for the role of folic acid in ameliorating hyperhomocysteinemia in humans, especially those
homozygous for the A222V mutation. Although the human
enzyme has not been fully characterized biochemically, our
experiments (Figure 7) indicate that addition of methyltetrahydrofolate or FAD protects the human wild-type and mutant enzymes against thermal inactivation. The upper panel
shows the protective effect of these compounds in crude extracts containing recombinant human enzyme expressed in E.
coli1, while in the lower panel lymphocyte extracts from Ala/
Ala (normal MTHFR) or Val/Val (mutant MTHFR) human
subjects have been used. Addition of FAD to crude extracts
protects both wild-type and mutant enzymes, and the protection is more dramatic with the mutant enzyme. Addition
of methyltetrahydrofolate to the crude extracts also protects
both the wild-type and mutant enzymes against thermal denaturation, with the more dramatic protection again being seen
with the mutant enzyme. In vivo, increased concentrations of
folate derivatives that are products or inhibitors of the reaction
will inhibit the reduction of CH2-H4 folate as well as stabilizing the enzyme. However, we assume that supplementation
with folic acid increases the concentration of all intracellular
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Figure 4. The A177V mutation leads to a thermolabile enzyme as
assessed by differential-scanning calorimetry. Measurements were
performed on wild-type and A177V MTHFR proteins at the indicated
subunit concentrations. Each data set has been offset by 20 kcal mol−1
K−1 for clarity, and the melting temperatures (Tm) are displayed alongside their respective peaks. A preliminary experiment in which the Tm
values of 22 μM wild-type and wild-type histidine-tagged MTHFR proteins were compared gave values of 58.4 and 58.6 °C, respectively, indicating that the His6 tag at the C-terminus did not affect the melting
temperature.

folate derivatives, including the substrate CH2 -H4 folate. The
results reported here suggest that increased folate, known to
lower homocysteine levels in normal subjects11 and in A→V
homozygotes,6 acts by suppressing loss of FAD from MTHFR.
Recent studies have demonstrated that folate deficiency
in humans leads to uracil misincorporation into DNA and
chromosome breakage, and have suggested that the 677C→T
polymorphism might provide protection against chromosome breakage when the concentration of intracellular folates
is low by sequestering folate in the CH2-H4 folate form that
is required for conversion of dUMP to dTMP.30 If the level
of methylenetetrahydrofolate is low and MTHFR is fully ac-
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tive, flux will favor methionine biosynthesis over synthesis of
thymidylate. Our studies suggest that wild-type MTHFR responds to low folate levels by undergoing flavin loss and inactivation. Our observations on bacterial and human MTHFR
provide a biochemical rationale for the effects of folate supplements in reducing plasma homocysteine levels in individuals
homozygous for the polymorphism. In addition, since folate
derivatives stabilize both the wild-type and mutant enzymes,
the benefit of folate supplementation should extend to individuals who are not homozygous for the polymorphism. Recent clinical studies suggest that individuals who are homozygous for the polymorphism might be particularly sensitive
to homocysteine lowering by folate, although nonmutant individuals do respond.31 Our results suggest that the activity
of both wild-type and mutant enzymes may be controlled by
the intracellular folate and FAD concentrations, and that the
677C→T mutation simply shifts the balance point at which enzyme inactivation occurs.
Methods
Overexpression and purification of wild-type and A177V mutant MTHFR.
Wild-type MTHFR was purified to homogeneity from E. coli strain
CAS-9 as described.24 Briefly, the coding sequence was placed into the
polylinker region of plasmid pTrc99A (Pharmacia) and transformed into
metF strain AB1909, which lacks a functional MTHFR and is auxotrophic for methionine, for overexpression. MTHFR was purified to homogeneity by batch chromatography on DEAE fast-flow Sepharose, FPLC
on Mono Q anion-exchange resin, and hydrophobic FPLC on Phenyl
Sepharose. This enzyme was used for structure determination. However, attempts to express the A177V protein in a similar manner led
to very low levels of expression, and the protein was too unstable to
survive the purification procedure. We therefore constructed strains
expressing C-terminally histidine(6)-tagged wild-type24 and A177V
MTHFR. Plasmids containing the coding sequences for these proteins
were used to transform E. coli strain BL21(DE3)recD+ (Novagen). This
strain contains a functional metF gene but only 1% of the MTHFR protein is wild-type and lacks the histidine tag. Histidine-tagged MTHFR
from these strains could be purified to homogeneity in a single step

Figure 5. a) The A177V mutation is associated with an enhanced rate of flavin dissociation. After dilution of a concentrated stock of enzyme
to the indicated subunit concentrations [Et], the initial rate of FAD dissociation was ascertained for wild-type (●) and A177V (■) enzymes. The solid
lines have been calculated assuming that the rate of flavin release varies as the square root of the enzyme concentration after dilution. Inset: The
change in fluorescence versus time is shown for wild-type (lower trace) and A177V (upper trace) enzymes diluted to 500 nM concentration. b) Protection of wild-type and A177V mutant enzyme against flavin loss after dilution in the presence of CH3-H4 folate. The initial rate of flavin loss from
500 nM wild-type (●) and A177V mutant (■) enzymes is plotted against the concentration of (6S)CH3-H4 folate monoglutamate (Eprova Pharmaceuticals) present after dilution. The initial rates have been corrected for fluorescence increases associated with the slow oxidation of CH3-H4 folate
catalyzed by the enzyme under aerobic conditions.
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40 μM FAD, 160 mM ammonium sulfate, and 8−13% polyethylene glycol (M r 8,000) at 4 °C, and belong to space
group C2 with unit cell dimensions a = 103.00 Å, b = 128.20
Å, c = 98.20 Å, and β = 121.60°, with three chains in the
asymmetric unit. The MAD experiment (three wavelengths)
was performed at CHESS beamline F2 with a crystal soaked
in mercuric acetate and flash frozen. The CCP4 suite of programs33 was used to locate the mercury sites by Patterson
methods. Phases were calculated using the MAD option
of MLPHARE33 (<m> = 0.44−2.9 Å), and solvent flattening
was performed with DM33. The model building for the three
chains in the asymmetric unit was done in O.34 X-PLOR35 was
used for refinement of the model in rounds that included
simulated annealing and refinement of individual atom Bfactors. A bulk solvent correction was applied.36

Figure 6. a) The location and environment of the Ala 177 that corresponds
to the site of the A→V polymorphism in human MTHFR. The view is approximately perpendicular to the barrel axis and oriented to show helix α5 and its neighboring barrel strands. Black dot surfaces trace the helix backbone from 171 to 176;
red surfaces represent the volume of alanine at position 177, and green surfaces a
valine substituted at position 177 which clearly overlaps the helix backbone. The
side chains of Lys 172, Asn 168, and Asp 165 that interact with FAD are drawn in
ball-and-stick mode with carbons in cyan. b) The tetramer of E. coli MTHFR, viewed
down the local two-fold axis. The asymmetric unit of the monoclinic cell contains
the three chains A, B, and C; the fourth chain of the tetramer (A’) is related to A by a
crystallographic two-fold axis. The C and B subunits can be superimposed on chains
A and A’ by a local dyad (perpendicular to the page) that is inclined by ~53° to the
crystallographic dyad along axis y. This local dyad is the only symmetry operator
that relates the chains of the tetramer to one another. Interfaces A−A’ and B−C are
formed by symmetric interactions between helices α7c, α7b, and α8. In contrast, the
A and B (or C and A’) chains are not related by a simple rotation of 360/nO; the B
chain is superimposed on the A chain by a rotation of 108° and a translation of ~7
Å. Helix 5, which may be critical in mediating the effects of mutation at position 177,
is drawn in red, and Ala 177 is white and surrounded by dot surfaces. The figure was
prepared using the program RIBBONS.37
by chromatography on Hi-Trap nickel agarose columns as described,24
and yielded enzymes with a full complement of bound FAD (four per
tetramer)24 and with comparable specific activity as measured by CH2H4 folate-menadione oxidoreductase assay.
Structure determination. The structure of E. coli MTHFR was determined by multiwavelength anomalous diffraction32 (MAD) using
mercury as the anomalous scatterer. Crystals suitable for data collection were obtained from 15% isopropanol, 100 mM MES pH 6.1,

Differential-scanning calorimetry. Differential-scanning calorimetry was performed by Craig Johnson of Calorimetry Sciences Corporation on a NANO differential-scanning calorimeter. The excess heat capacity <C p> for thermal
denaturation of purified enzyme in 50 mM potassium phosphate buffer, pH 6.3, containing 0.3 mM EDTA and 10%
glycerol was measured for the indicated concentrations of
wild-type and A177V histidine-tagged proteins over a temperature range from 15 to 75 °C. The temperature was increased at 1 °C min−1.
Fluorimetry. Concentrated enzyme (~200 mM) was diluted to concentrations between 0.25 and 7 μM and the increase in fluorescence, a measure of FAD dissociation, was
monitored over time. Fluorescence was measured with excitation at 390 nm and emission at 525 nm in an ISA JY/SPEX
fluorimeter.
Coordinates. The coordinates have been deposited in
the Protein Data Bank (accession code 1B5T).
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Figure 7. Stabilization of normal and mutant human
MTHFR (hMTHFR) by CH 3-H4 folate and FAD against
heat inactivation. In each panel, the dark-gray columns
represent data obtained for normal (Ala) MTHFR, while
the light-gray stippled columns represent data obtained
for mutant (Val) MTHFR. a,b) Stabilization of recombinant wild-type and A222V MTHFR expressed in E. coli1.
Aliquots of crude sonicate supernatants containing 100
μg protein were preincubated at 46 °C in the presence of
the indicated concentrations of (6-RS)CH3-H4 folate (a) or
FAD ( b). After cooling to 37 °C, additional (6-RS)CH3-H4
folate and/or FAD were added to the reaction mixtures
and the samples were assayed in duplicate using the CH3H4 folate-menadione oxidoreductase assay1, 38. Values reported have been corrected for the activity in a control
JM105 strain1. The bars represent the mean ±s.d. of data
obtained from three experiments. c, d) Stabilization of
normal (Ala/Ala) and mutant (Val/Val) MTHFR in human
lymphocyte extracts (90 μg of protein) by CH3-H4 folate
(c) and FAD (d). The bars represent the mean ±s.d. of data
obtained from duplicate assays of the enzyme extracts of
three individuals.
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Table 1. X-ray data collection, MAD phasing, and structure refinement
Data collection
Crystal
Wavelength (Å)
λ1
1.012
λ2
1.010
λ3
1.008
MAD phasing
Resolution (Å)2
13.64
<m>
0.462
Statistics after refinement
Resolution (Å)
Reflections3
Protein + FAD atoms
Solvents
Average B (protein)
Average B (solvents)

Resolution (Å)
2.5
2.5
2.5
8.92
0.423
20.0–2.5
36,486
6,378
184
21.36 Å2
26.20 Å2

Completeness (%)
97.3 (81.4)
97.2 (80.4)
97.3 (83.0)
6.63
0.499

No. of observations
375,635
376,949
377,615

5.27
0.513

4.38
0.454

Rwork
Rfree
Deviations in
Bond length
Bond angles
Improper dihedrals

Unique reflections
36,377
36,492
36,508
3.74
0.412

3.27
0.434

Rsym1
0.060 (0.091)
0.066 (0.097)
0.068 (0.101)
2.90
0.435

0.212
0.263
0.008 Å
1.4°
1.2°

1. Values in parentheses are for outermost bins.
2. High-resolution limit for bins.
3. No σ cutoff.
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